2 weeks Ago By ABMN Staff
Context Therapeutics Inc. ( NASDAQ:CNTX – Free Report ) – Equities researchers at HC Wainwright dropped their FY2024 EPS estimates for shares of Context Therapeutics in a note issued to investors on Thursday, November 7th. HC Wainwright analyst E.
Bodnar now expects that the company will post earnings per share of ($0.53) for the year, down from their prior forecast of ($0.52).
HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.
51) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2024 earnings at ($0.04) EPS, FY2025 earnings at ($0.
37) EPS, FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.64) EPS.
Context Therapeutics Stock Up 0.5 % NASDAQ:CNTX opened at $2.05 on Monday.
Context Therapeutics has a 52 week low of $0.77 and a 52 week high of $2.75.
The stock’s 50-day moving average price is $2.08 and its 200-day moving average price is $2.07.
The stock has a market capitalization of $153.75 million, a PE ratio of -2.14 and a beta of 2.
25. Hedge Funds Weigh In On Context Therapeutics A number of hedge funds have recently bought and sold shares of the business. Great Point Partners LLC purchased a new stake in shares of Context Therapeutics in the second quarter valued at approximately $14,876,000.
Blue Owl Capital Holdings LP purchased a new stake in Context Therapeutics in the 2nd quarter worth $10,348,000. Driehaus Capital Management LLC acquired a new position in Context Therapeutics during the second quarter worth $4,527,000. Nantahala Capital Management LLC purchased a new position in Context Therapeutics during the second quarter valued at $3,881,000.
Finally, Affinity Asset Advisors LLC lifted its holdings in Context Therapeutics by 392.4% during the second quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after purchasing an additional 1,290,323 shares in the last quarter.
Hedge funds and other institutional investors own 14.03% of the company’s stock. About Context Therapeutics ( Get Free Report ) Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Recommended Stories Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
